Nevanac 3-Month Safety Study With QID Dosing

Completed · Phase 3

Conditions studied: Cataract

In brief

The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.

Key facts

Study ID

NCT00332774

Run by

Alcon Research

People needed

149

Starts

2006-02-01

Expected to finish

2006-12-01

Last updated by the study team

2012-03-05

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients of any race or sex ages 10 years or older undergoing cataract extraction with planned implantation of a posterior chamber intraocular lens.
• Other protocol-defined inclusion criteria may apply.

You may not qualify if…

• Under 10
• Other protocol-defined exclusion criteria may apply

Where it is running

• Contact Alcon for Trial Locations — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.